Chimeric microtubule disruptors

Mathew P Leese, Fabrice Jourdan, Meriel R Kimberley, Gyles E Cozier, Nethaji Thiyagarajan, Chloe Stengel, Sandra Regis-Lydi, Paul A Foster, Simon P Newman, K Ravi Acharya, Eric Ferrandis, Atul Purohit, Michael J Reed, Barry V L Potter

    Research output: Contribution to journalArticlepeer-review

    23 Citations (Scopus)


    A chimeric approach is used to discover microtubule disruptors with excellent in vitro activity and oral bioavailability; a ligand-protein interaction with carbonic anhydrase that enhances bioavailability is characterised by protein X-ray crystallography. Dosing of a representative chimera in a tumour xenograft model confirms the excellent therapeutic potential of the class.
    Original languageEnglish
    Pages (from-to)2907-9
    Number of pages3
    JournalChemical Communications
    Issue number17
    Publication statusPublished - 2010


    Dive into the research topics of 'Chimeric microtubule disruptors'. Together they form a unique fingerprint.

    Cite this